Novo Nordisk’s (NVO) head of public affairs in the U.S. Jennifer Duck has departed the company, Reuters’ Maggie Fick and Dan Levine report, citing an internal memo. The company, much like other drugmakers, is facing pressure from the Trump administration on drug pricing and is trying to regain lost ground to Eli Lilly (LLY), the authors note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Midday Fly By: U.S. oil majors rise on Venezuela news, Versant completes spinoff
- Eli Lilly Stock (LLY) Falls 4% as Rival Novo Nordisk Begins Selling Obesity Pill in U.S.
- Hims & Hers again left off Novo partner list, says Citi
- LifeMD expands collaboration with Novo Nordisk for Wegovy pill
- Weight Watchers expands GLP-1 platform with access to Wegovy pill